2017
DOI: 10.15761/tit.1000237
|View full text |Cite
|
Sign up to set email alerts
|

Campath induction is associated with equalization of short term outcomes in renal retransplantion (but long-term outcomes are worse)

Abstract: Introduction: Few studies have evaluated the use of Alemtuzumab (Campath) induction in renal retransplantation (RRT).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 26 publications
(45 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?